Measles, Mumps, Rubella and Varicella virus vaccine live(Merck & Co., Inc.)

Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and Director SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today announced a CEO succession, in which co-founder and CEO Richard Lowenthal will no longer serve as an employee and officer of the company effective July 6, 2026. The Board has appointed Donn Casale, currently President, as CEO and Director effective July 7, 2026. “Since co-founding ARS Pharma in 2015, Rich was integral to guiding the company from development to establishing neffy ® as a leading treatment for adults and children with Type 1 allergic reactions, including anaphylaxis, and we are grateful for his many contributions,” said Pratik Shah, chairman of the Board of Directors. “As we look ahead, Donn is a seasoned business leader with deep operational and financial acumen, and proven commercial track record, particularly in growing adoption and share in large, consumer-driven markets. We are confident that he has the right background and experience to drive the company through its next phase, growing the neffy franchise and positioning ARS Pharma for both near and long-term value-creation.” Mr. Casale brings more than 25 years of biopharmaceutical business and commercial leadership, with a track record of scaling innovative products in large, patient-driven healthcare markets. Prior to ARS Pharma, he served as Chief Commercial Officer at Dynavax Technologies, where he built the U.S. commercial infrastructure and helped scale the hepatitis B vaccine HEPLISAV-B® from launch to more than $300 million in annualized revenue and over 50% U.S. market share, positioning the company for Sanofi’s $2.2 billion acquisition. Before Dynavax, Mr. Casale held leadership positions in marketing and sales operations at Depomed, supporting the commercialization of GRALISE® and NUCYNTA®. Earlier in his career, he spent 14 years at Merck in progressive roles across sales, marketing, and corporate strategy, contributing to the successful launches of ZOSTAVAX®, GARDASIL®, ROTATEQ®, and PROQUAD®. “I am excited by the opportunity to lead ARS Pharma through its next evolution,” said Mr. Casale. “ neffy is a transformational product for patients, backed by a foundational intranasal technology platform, and I am confident in our ability to grow its impact in the years to come. I’m grateful for the foundation Rich and the Board have built, and I look forward to working alongside our team to increase access, accelerate adoption, and expand the reach of ARS Pharma, delivering on the promise that our treatments can have on patients worldwide.” About neffy ® neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in adults and children who weigh 33 lbs. or greater. INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray) INDICATION neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 33 lbs. or greater. IMPORTANT SAFETY INFORMATION neffy contains epinephrine, a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes. Always carry two neffy nasal sprays with you because you may not know when anaphylaxis may happen and because you may need a second dose of neffy if symptoms continue or come back. Each neffy contains a single dose of epinephrine. neffy is for use in the nose only. Use neffy right away, as soon as you notice symptoms of an allergic reaction. If symptoms continue or get worse after the first dose of neffy , a second dose is needed. If needed, administer a second dose using a new neffy in the same nostril starting 5 minutes after the first dose. Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed after using neffy . Tell your healthcare provider if you have underlying structural or anatomical nasal conditions, about all the medicines you take, and about all your medical conditions, especially if you have heart problems, kidney problems, low potassium in your blood, Parkinson's disease, thyroid problems, high blood pressure, diabetes, are pregnant or plan to become pregnant, or plan to breastfeed. Tell your healthcare provider if you take or use other nasal sprays or water pills (diuretics) or if you take medicines to treat depression, abnormal heart beats, Parkinson's disease, heart disease, thyroid disease, medicines used in labor, and medicines to treat allergies. neffy and other medications may affect each other, causing side effects. neffy may affect the way other medicines work, and other medicines may affect how neffy works. neffy may cause serious side effects. If you have certain medical conditions or take certain medicines, your condition may get worse, or you may have more or longer lasting side effects when you use neffy . Common side effects of neffy include: nasal discomfort, headache, throat irritation, chest and nasal congestion, feeling overly excited, nervous or anxious, nose bleed, nose pain, sneezing, runny nose, dry nose or throat, tingling sensation, including in the nose, feeling tired, dizziness, nausea, and vomiting. Tell your healthcare provider if you have any side effects that bother you or that do not go away after using neffy . These are not all of the possible side effects of neffy . Call your healthcare provider for medical advice about side effects. To report side effects, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or the FDA at 1-800-FDA-1088 or . Please see the full Prescribing Information and Patient Information for neffy . About Type I Allergic Reactions Including Anaphylaxis Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an emergency. About ARS Pharmaceuticals, Inc. ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy ® (trade name EUR neffy ® in the EU and UK and 优敏速 ® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 15 kg or greater. For more information, visit . Forward-Looking Statements Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the belief that ARS Pharma is well-positioned to drive meaningful market share growth; expectations regarding prescription renewals and demand generally; ARS Pharma’s plans to increase access to, accelerate adoption of, and expand the reach of ARS Pharma and of neffy ; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “expect,” “if,” “may,” “on track,” “potential,” “plan,” “will,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks associated with transitions of members of the senior management team; potential safety and other complications from neffy ; the ability to maintain regulatory approval for neffy in its currently approved indications; the scope, progress and expansion of developing and commercializing neffy ; the risk that personnel costs will be higher than anticipated; the scope, progress and expansion of developing our intranasal epinephrine technology; clinical trial results; the potential for governments and payors to delay, limit or deny coverage for neffy ; the size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharma’s ability to protect its intellectual property position; and the impact of government laws, regulations and policies. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption 'Risk Factors' in ARS Pharma's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission ('SEC'), and as updated by the 'Risk Factors' in ARS Pharma's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 15, 2026 . These documents can also be accessed on ARS Pharma’s website at by clicking on the link “ Financials & Filings ” under the “Investors & Media” tab. The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law. For more information, visit , and follow us on LinkedIn and X . Investor Contact: Monique Allaire, THRUST monique@thrustsc.com Media Contact: Nabeelah Khan nabeelahk@ars-pharma.com

今晚，大咪给 MRCLUB 的小伙伴们分享一个最新的药物销售排名榜单，看看有你做过的品种吗？ 2025年全球畅销药物50强 （单位：百万美元） # 品牌 通用名 公司 25销售 增幅 1 可瑞达 帕博利珠单抗 默沙东 31,680 7.5% 2 穆峰达 替尔泊肽 礼来 22,965 99.0% 3 诺和泰 司美格鲁肽 诺和诺德 19,206 5.6% 4 达必妥 度普利尤单抗 赛诺菲/再生元 17,736 20.2% 5 喜开悦 利生奇珠单抗 艾伯维 17,562 49.9% 6 艾乐妥 阿哌沙班 BMS/辉瑞 14,443 8.3% 7 兆珂 达雷妥尤单抗 强生 14,351 23.0% 8 必妥维 比克恩丙诺片 吉利德科学 14,300 6.7% 9 Zepbound 替尔泊肽 礼来 13,542 174.9% 10 诺和盈 司美格鲁肽 诺和诺德 11,955 35.9% 11 欧狄沃 纳武利尤单抗 BMS 10,049 8.0% 12 欧唐静 恩格列净 勃林格/礼来 9,932 4.8% 13 罗可适 奥瑞利珠单抗 罗氏 8,436 3.9% 14 安达唐 达格列净 阿斯利康 8,492 10.0% 15 瑞福 乌帕替尼 艾伯维 8,304 39.1% 16 诺欣妥 沙库巴曲缬沙坦 诺华 7,748 -0.9% 17 泰瑞沙 奥希替尼 阿斯利康 7,254 10.2% 18 可善挺 司库奇尤单抗 诺华 6,668 8.6% 19 沛儿 肺炎球菌结合疫苗 辉瑞 6,494 1.3% 20 维达全 氯苯唑酸葡胺 辉瑞 6,380 17.0% 21 喜达诺 乌司奴单抗 强生 6,078 -41.3% 22 英飞凡 度伐利尤单抗 阿斯利康 6,063 28.5% 23 唯择 阿贝西利 礼来 5,723 7.8% 24 佳达修 HPV疫苗 默沙东 5,233 -39.0% 25 特诺雅 古塞奇尤单抗 强生 5,155 40.5% 26 罗视佳 法瑞西单抗 罗氏 4,936 6.1% 27 凯丽隆 琥珀酸瑞波西利 诺华 4,783 57.7% 28 欣安立适 重组带状疱疹疫苗 GSK 4,687 5.8% 29 修美乐 阿达木单抗 艾伯维 4,540 -49.5% 30 全欣达 奥法妥木单抗 诺华 4,426 37.3% 31 复必泰 mRNA新冠疫苗 辉瑞/BioNTech 4,367 -18.4% 32 爱博新 哌柏西利 辉瑞 4,122 -5.6% 33 全再乐 糠酸氟替卡松/乌美溴铵/维兰特罗吸入粉雾剂 GSK 3,934 10.5% 34 恩瑞舒 阿巴西普 BMS 3,705 0.6% 35 诺和忻 司美格鲁肽片 诺和诺德 3,339 -5.2% 36 瑞复美 来那度胺 BMS 2,951 -48.9% 37 逸沃 伊匹木单抗 BMS 2,900 14.6% 38 亿珂 伊布替尼 艾伯维/强生 2,869 -14.3% 39 Pomalyst/Imnovid 泊马度胺 BMS 2,733 -22.9% 40 PROQUAD/M-M-R II/VARIVAX 麻腮风-水痘相关疫苗 默沙东 2,451 -1.4% 41 Paxlovid 奈玛特韦/利托那韦 辉瑞 2,362 -58.7% 42 利布洛泽 罗特西普 BMS 2,327 31.2% 43 万凯锐/瑞卡必 卡替拉韦/利匹韦林 GSK/ViiV 1,847 38.4% 44 Breyanzi 利基迈仑赛 BMS 1,358 81.8% 45 Opdualag 纳武利尤单抗/瑞拉利单抗 BMS 1,185 27.7% 46 迈凡妥 玛伐凯泰 BMS 1,068 77.4% 47 艾普特 卡替拉韦 GSK/ViiV 578 57.1% 48 热珀西亚 奥扎莫德 BMS 577 1.9% 49 施达赛 达沙替尼 BMS 493 -61.7% 50 Abecma 艾基维仑赛 BMS 427 5.2% 在过去一年，跨国药企最引人关注的竞争依然发生在榜单头部品种之间，按单一品牌药销售额计算，默沙东的可瑞达（Keytruda，帕博利珠单抗）守住了第一的位置，不过，如果按同一活性成分合并计算，礼来的替尔泊肽和诺和诺德的司美格鲁肽销售额已经超过了可瑞达。 如果把以上几个头部品牌放到一边看，2025 年的全球药物销售榜显示，行业中具备规模化优势的专科药大品种的销售并没有进入平台期，仍在持续增长。 可以看到，喜开悦（Skyrizi，利生奇珠单抗）、瑞福（Rinvoq，乌帕替尼）、达必妥（Dupixent，度普利尤单抗）、兆珂（Darzalex，达雷妥尤单抗）、特诺雅（Tremfya，古塞奇尤单抗）和凯丽隆（Kisqali，琥珀酸瑞波西利）等大品种仍保持较强的增长势头。 另外，尽管整个制药行业管线在 2025 财年出现了收缩，免疫类药物仍是少数几个仍在扩张的大型治疗领域之一，增幅达到 20.6%。 还有一个值得注意的地方，在这份榜单中，百时美施贵宝（BMS）入选品种多达 13 个，数量远远高于其他跨国药企，显示了 BMS 深厚的产品组合，在抗凝、免疫肿瘤、血液肿瘤、细胞治疗、心血管等多个领域，都可以看到 BMS 的品种。 在头部跨国药企中，百时美施贵宝的产品梯队的换挡是比较成功的，可以看到，这 13 个品种中既有欧狄沃、利布洛泽、Breyanzi、迈凡妥等增长资产，也有仿制药冲击下的瑞复美、泊马度胺、施达赛等已经明显下滑的老品种，依靠新品接力，2025年，BMS 实现了全年 482 亿美元的营收。 之前大咪曾多次分享过 BMS 新组团队的岗位信息，感兴趣的小伙伴们可以继续保持关注，遇到自己心仪的岗位抓紧投递简历。 上述排名由 Drug Discovery and Development 基于原始申报文件整理，涵盖了全球 50 强药企在 2025 财年报告的最畅销药物。 近日热点： 轻装拜访！诺华挑战夏季着装惯例 默沙东公布新一批裁员人数 吉利德科学推出LGBTQ+对话工具 34种药品进入新一批带量采购名单 国药集团，又控股一家公司 第12批国采规则流出，7个变化 实控人被立案，泰格医药更换总经理 君实生物副总、核心技术人员辞任 35岁+医药代表，还有更多出路吗？ 借助第三方“带金销售”没路走了！ PD-1新标杆！H药获批新适应症 销售代表起步，今日就任药企董事长 第九批国采，一品种被取消中选资格 南新制药三高管被罚 诺华双靶组合在华获批第四个适应症 106亿美元！GSK买下Nuvalent 0元转让股权！90后“药二代”接棒大药企 2026国家医保目录调整最新进展 全球首发！诺和杰®在中国率先上市 代表交流： 拜访客户，这6个边界感很重要 优秀的医药代表都是“问题猎手” 优秀的医药代表都是问题猎手（二） 四位日本医药代表的一天 默克名言，强生信条，你更认可哪个？ 什么是“重磅炸弹”药物？ 外企裁员，这三种说法你要了解下 美国医药代表在官方职业体系位置 新规之下，医药代表的三个重要职能 什么是医学联络官（MSL）？ 最新职位： 百时美施贵宝新业务线热招 亚虹医药新团队全国热招中 安进全国职位来了！ 夏季新职！拜耳全国热招职位 最新药企内部招聘（6月13日更新） 医药代表 伴您成长！